Orris

Asthma management

Asthma management can cover different things depending on what you need. Let me narrow this down before pulling from the medical library.
Asking for Preferences
Asthma management can cover different things depending on what you need. Let me narrow this down before pulling from the medical library.
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching PubMed

asthma management

Asthma Management

Asthma management has two pillars: long-term (chronic) control to prevent symptoms/exacerbations, and acute exacerbation treatment when control breaks down. Modern guidelines (GINA) frame both around a stepwise, control-based approach rather than fixed severity categories, because a patient's asthma can move up or down in severity over time depending on adherence, triggers, and treatment response - Fishman's Pulmonary Diseases and Disorders, p. 810.

1. Assessing Control

Before choosing therapy, control is assessed using:
  • Daytime symptoms in the last week
  • Activity limitation
  • Nocturnal symptoms/awakenings
  • Need for reliever (SABA) use
  • Lung function (spirometry/PEFR)
  • Number of exacerbations in the last week/year
GINA sorts patients into four categories: controlled (maintain or step down), partly controlled (consider stepping up), uncontrolled (step up until controlled), and exacerbation (treated via a separate acute algorithm) - Fishman's Pulmonary Diseases and Disorders, p. 810.

2. Chronic (Stepwise) Therapy

Step 1 - Mild/intermittent symptoms: A short-acting beta2-agonist (SABA) via MDI for relief. Many current guidelines now favor low-dose ICS-formoterol as the reliever even at this step, since asthma is fundamentally an inflammatory disease and reliance on SABA alone is discouraged. Reliever use more than 3 times/week signals the need for controller therapy.
Steps 2-3: Add a daily inhaled corticosteroid (ICS) - the cornerstone controller for underlying airway inflammation. Start low-to-intermediate dose (e.g., beclomethasone ~200 mcg BID or equivalent); step down if controlled after 3 months. If symptoms persist, add a long-acting beta-agonist (LABA) as a fixed-dose combination inhaler with the ICS (more effective than two separate devices). Leukotriene receptor antagonists are a less-effective alternative add-on.
Steps 4-5 (poorly controlled/severe asthma): Add a long-acting muscarinic antagonist (e.g., tiotropium) to medium/high-dose ICS/LABA - shown to reduce exacerbations and improve lung function. If still uncontrolled, escalate to high-dose ICS/LABA, and consider biologic therapy for severe, phenotype-specific disease:
  • Anti-IL-5 (mepolizumab, reslizumab): reduce eosinophilic exacerbations
  • Anti-IL-5Rα (benralizumab): reduces exacerbations, allows systemic steroid reduction
  • Anti-IL-4Rα (dupilumab): benefits patients with eosinophils >300 cells/mm3 or FeNO ≥25 ppb
Chronic oral corticosteroids are reserved as a last resort given their side-effect burden, titrated to the lowest effective dose - Fishman's Pulmonary Diseases and Disorders, p. 810-811; Washington Manual of Medical Therapeutics.
Non-pharmacologic measures: trigger avoidance (aeroallergens, occupational agents, house dust mite reduction), and vaccination - annual influenza vaccine and pneumococcal vaccine (Pneumovax) for adults 19-64 with chronic illness including asthma.

3. Acute Exacerbation Management

The goal is rapid reversal of airflow obstruction, adequate oxygenation, and reduction of inflammation - Tintinalli's Emergency Medicine, p. 504.
  • Bronchodilators: Repetitive/continuous inhaled SABA is first-line. Response to the first 60-90 minutes of treatment (three SABA doses q20min) predicts need for hospitalization better than initial severity.
    • Mild-moderate: albuterol 2-6 puffs MDI+spacer or 2.5 mg nebulized, repeated q20min.
    • Severe: albuterol 2.5-5 mg + ipratropium bromide 0.5 mg nebulized q20min, or continuous albuterol 10-15 mg/hour (with telemetry monitoring).
  • Systemic corticosteroids: Given promptly to all patients with an exacerbation to speed resolution.
  • Escalation/monitoring: Chest x-ray only if pneumothorax, pneumonia, or another complication is suspected (fewer than a third of hospitalized patients have an abnormal film). Rising or normal PaCO2 (>42 mmHg) in a tachypneic asthmatic is an ominous sign of fatigue and impending respiratory failure, not improvement.
  • Admission threshold: Low threshold for admission with recent hospitalization, failure of aggressive outpatient oral corticosteroid therapy, or a prior near-fatal attack.
  • Near-fatal/status asthmaticus: Severe attacks unresponsive to usual bronchodilator/corticosteroid doses require escalation to ICU-level care; risk factors for asthma death should prompt patients to seek care early - Rosen's Emergency Medicine; Tintinalli's Emergency Medicine.

Supplementary evidence check

Recent systematic reviews (2024) support adjunctive, non-pharmacologic strategies that complement (not replace) the above: breathing exercises may improve quality of life and reduce bronchodilator need (PMID: 39028058), structured nurse-led asthma education/control programs in primary care (PMID: 38804437), and combined lifestyle interventions (exercise, smoking cessation, diet) for asthma/COPD prevention and control (PMID: 38794757). None of these contradict standard stepwise pharmacologic management - they reinforce it.
Bottom line: Chronic asthma is managed with a stepwise ICS-based regimen (add LABA, then LAMA/biologics as needed) guided by ongoing control assessment, while acute exacerbations are treated with frequent SABA, systemic corticosteroids, and anticholinergics for severe cases, with a low threshold for hospital admission in high-risk patients.
This is a shared conversation. Sign in to Orris to start your own chat.